Predictions regarding the supply of 99Mo and 99mTc when NRU ceases
  production in 2018 by Ross, C. K. & Diamond, W. T.
 Predictions regarding the supply of 99Mo and 99mTc when NRU 
ceases production in 2018 
 
C. K. Ross1,2 and W. T. Diamond3 
June 2015 
 
1 Retired NRC physicist, Ottawa, ON, Canada, carlkross@gmail.com 
3 Retired AECL physicist, Deep River, ON, Canada, diamond_w45@yahoo.ca 
2Author to whom correspondence should be addressed 
E-mail:  carlkross@gmail.com  
(Manuscript submitted to Physics in Canada) 
 
Page 2 of 21 
 
 
Summary 
The NRU reactor in Chalk River had been scheduled to stop producing medical isotopes by the 
end of 2016 but the Government of Canada recently announced that it will remain available to 
support isotope production until its operating license expires on 31 March, 2018. NRU has the 
capability of producing up to 80 % of the world’s requirements for 99Mo but is presently 
producing less than 20 %. There are a number of initiatives underway, both within Canada and 
around the world, to find alternative ways of producing 99Mo or its daughter, 99mTc. We 
examine the status of the main proposals and conclude that it will be challenging for any of 
them to meet the required demand by the end of 2016.  An additional year should be enough 
time for some of the proposals to complete the development of manufacturing facilities and 
achieve regulatory approval.  It is likely that these operators will have enough production 
capability to make up for the shortfall when the NRU operating license expires.
Page 3 of 21 
 
INTRODUCTION 
 
The most widely used isotope for medical imaging is 99mTc. World-wide, approximately 30 
million doses are used each year and usage is growing at a rate of a few percent per year[1]. 
Each dose of 99mTc is about 20 mCi1 and the current purchase price for a single dose is about 
$40. Most 99mTc, which has a half-life of about 6 hours, is derived from the decay of the parent 
isotope, 99Mo. Because the half-life of 99Mo is about 66 hours, the time scale during which 99mTc 
can be stored and shipped is extended by an order of magnitude compared to the direct 
production of 99mTc. 
Research reactors have been the main source of 99Mo for several decades[2]. The fission of 235U 
leads to many fission products, including 99Mo, which is produced with an efficiency of about 
6 %. The 99Mo is extracted from the 235U targets, purified, converted to molybdate, 2-4MoO , and 
loaded onto alumina columns. Each column is loaded into a lead-lined technetium generator, 
containing up to 10 Ci of 99Mo. As the 99Mo decays, it forms pertechnetate, -4TcO , which can be 
washed off the column using a saline solution. The generator, which is about the size of a large 
thermos, can be milked repeatedly over a period of two weeks to recover additional -4TcO , as 
illustrated in Figure 1. 
Three reactors, NRU in Canada, HFR in the Netherlands and SAFARI-1 in South Africa, account 
for more than 80 % of the world’s supply of 99Mo. The supply was stable for several decades but 
the unexpected shut-down of NRU in 2007 led to a shortage and what has come to be known as 
the isotope crisis[3]. It became generally recognized that the world’s supply of its most 
important medical isotope relied on a few aging reactors whose future was uncertain because 
of licensing issues, technical challenges or government support. 
A second challenge that affects most of the reactors over the longer term is the desire to limit 
the amount of highly-enriched uranium (HEU) in circulation. Although low-enriched uranium 
(LEU) can be used as fission targets for 99Mo production only two smaller producers (SAFARI-1 
and OPAL) have successfully converted.  
The isotope crisis led to an urgent effort to look for options to maintain a reliable supply of 
99Mo. In the US, the National Nuclear Security Administration (NNSA) made funds available to 
support new proposals. In Canada, Natural Resources Canada (NRCan), which oversees the 
operation of the NRU reactor, called for proposals to look for alternative ways of producing 
                                                     
1
 The SI unit for activity is the Bq. However, the Ci (or mCi) is still widely used in nuclear medicine. One Ci is equal 
to 37 GBq. 
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99Mo.  In this article we will focus on those projects which are most likely to make a significant 
contribution to 99Mo or 99mTc production when NRU shuts down in the spring of 2018. 
BASIC REQUIREMENTS 
 
A successful proposal to produce large quantities of 99Mo or 99mTc on a regular basis must meet 
a number of requirements. The basic physics must be sound and used to show adequate 
production rates. Engineering challenges, such as heat dissipation, the handling of radioactive 
targets, the disposal of radioactive waste and ease of maintenance must be addressed. A 
suitable technique must be available for extracting the 99mTc with high efficiency. Regulatory 
approval related to radiation safety and patient safety must be obtained. The cost per unit dose 
must be shown to be competitive with other proposals. 
Options for producing 99Mo/99mTc can be divided into two broad categories. The first is based 
on neutron-induced fission of 235U. The fission route is exemplified by current reactor 
production either using HEU or LEU targets[2]. The fission of 235U can also be achieved using sub-
critical assemblies which are driven by a particle accelerator that serves as a source of 
neutrons[4].  
The second approach is based on nuclear reactions which lead to either 99Mo or 99mTc directly. 
Although there are several choices, three reactions have received most attention. The first[5] is 
the neutron capture reaction by 98Mo, leading to 99Mo. Usually the 98Mo targets are irradiated 
in a nuclear reactor because the fluence rate from other neutron sources is not large enough to 
be relevant. The second[6] is the photoneutron reaction on 100Mo which can be written as 
100Mo (, n) 99Mo. The threshold for this reaction is 9 MeV and the peak of the giant dipole 
resonance lies at about 14.5 MeV.  A suitable photon beam can be generated using an electron 
linear accelerator (linac) and a bremsstrahlung radiator. The third reaction[7] is induced by a 
proton beam generated by a cyclotron striking a target of 100Mo. In this case, the reaction can 
be written as 100Mo (p, 2n) 99Tc and leads directly to both 99Tc and 99mTc. It is the metastable 
state that is of interest for imaging, but the ground state component will compete with the 
metastable state when the isotope is tagged to biologically active molecules.  
PRODUCTION YIELDS 
 
An unusual unit, referred to as the six-day curie, is used presently for the sale and delivery of 
99Mo. A six day curie is defined[2] as the amount of 99Mo activity left six days after the generator 
has left the producer’s facilities. Six days represents more than two half-lives and suggests that 
only a little more than 20 % of the 99Mo produced in the reactor is available in the clinic. The 
Page 5 of 21 
 
global demand for 99Mo is estimated to be about 10,000 six-day curies per week[1] and that for 
Canada about 420 six-day curies per week[8]. 
The concept of the six-day curie may not be particularly relevant for some of the new modes of 
production and it has no relevance at all for 99mTc produced directly by cyclotrons where 99Mo 
plays no role. Thus, it is worth considering production requirements from the known 
consumption rates of 99mTc. There are about 5500 99mTc scans per day in Canada, each requiring 
about 20 mCi or a total of 110 Ci. 99mTc decays with a half-life of about six hours so allowing for 
scans to be spread out over a working day would require about 220 Ci available at the 
beginning of each day. This amount of 99mTc can be obtained by milking 280 Ci of 99Mo which 
would be the total inventory of 99Mo required. Over 24 hours, this inventory would decay by 
60 Ci which is the amount of 99Mo that would need to be replaced on a daily basis. Allowing 
about a day for source preparation and shipping, would suggest that a national facility 
producing about 80 Ci of 99Mo per day, would meet Canada’s requirements. This is more than a 
factor of three less than the present production rate. This estimate is consistent with work 
carried out at Idaho National Laboratories where they showed that a daily production rate of 
25 Ci, if efficiently processed and delivered, could supply the state of Florida which has a 
population about half that of Canada[9]. 
For an arbitrary radioisotope, the activity per unit volume, A , after an irradiation time, t ,  is 
given by  
 (1 ),tA n e          (1) 
where   is the particle fluence rate, n  is the number of target atoms per unit volume and   is 
the cross section for producing an atom of the desired isotope. The product of these three 
terms gives the atomic production rate. The quantity in parentheses accounts for the decay of 
each atom where   is the decay constant. This quantity reaches a value close to unity after 
about five half-lives of irradiation (sometimes called the saturated yield) at which point the rate 
of production and of decay are equal. 
The total production rate is obtained by integrating Eq. (1) over the volume of irradiated target 
atoms. The cross section for a given reaction is fixed so the production rate can only be 
changed by changing the fluence rate of the incident particles or the number of target atoms 
irradiated.  The cross section for the production of 99Mo by 235U fission is about 36 b. This is to 
be contrasted with the maximum 100Mo (, n) 99Mo and 100Mo (p, 2n) 99Tc cross sections which 
are less than 0.25 b. Furthermore, the volume of target material that can be irradiated by either 
an electron accelerator or cyclotron is much smaller than that of a reactor. 
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Thus, a single 10 MW reactor, such as the MAPLE[2], is capable of producing the world’s 
requirements of 99Mo/99mTc, while about 200 cyclotrons or 50 linacs would be required. Two 
35 MeV, 50 kW linacs could supply all of Canada’s present requirements for 99Mo.  
99MTC EXTRACTION 
 
No matter what reaction is used to produce 99Mo or 99mTc, a process must be available to 
extract efficiently the 99mTc from the molybdenum matrix. In the case of fission, there is no 
molybdenum present to start with, so when the molybdenum is separated from the 235U 
targets, the 99Mo isotope is only diluted by whatever other molybdenum isotopes have been 
produced as fission products. The resulting material is said to have high specific activity, 
typically greater than 10,000 Ci/g. In this case, several curies of 99Mo can be bound to an 
alumina column a few centimeters in length, as described in the Introduction and illustrated in 
Figure 2. The resulting technetium generator is a simple, passive device that is easy to use and 
is presently the most widely used method of obtaining 99mTc. An advantage of continuing to 
derive 99Mo as a fission product is that the existing technetium generators can be used, so that 
from the point of view of the user nothing changes. 
The two nuclear reactions that are being proposed to produce 99Mo require starting with a 
molybdenum target. In these cases, only a small fraction (ppm) of the initial target is converted 
to 99Mo and the resulting material is said to have low specific activity, typically in the range of 1 
to 10 Ci/g. The standard alumina column cannot be used in this case because the column would 
become impractically long. A 100Mo target is also used In the case of the (p, 2n) reaction that is 
used to produce 99mTc directly. Several techniques have been developed over the years to 
separate 99mTc from a molybdenum matrix[10]. We will briefly summarize the three that have 
received most attention. In all cases, the first step is to dissolve the molybdenum target and 
this can be done using a concentrated solution of hydrogen peroxide. 
Organic Solvent Extraction (MEK Process) 
 
In this technique, the aqueous solution containing the molybdenum and 99mTc decay product is 
mixed with an immiscible organic solvent, methyl ethyl ketone (MEK). Technetium oxide is 
soluble in MEK but not molybdenum oxide. After agitation, the MEK will float to the surface of 
the aqueous solution and can be removed, carrying with it the 99mTc. The MEK is evaporated 
leaving behind the technetium oxide. The cycle can be repeated several times as the 99Mo 
decays to 99mTc. This approach has a long history so its strengths and weaknesses are well 
established. It is being used by the Winnipeg Health Sciences Centre[11] to process targets 
irradiated using the linac at the Canadian Light Source (CLS). 
Page 7 of 21 
 
Thermal Separation 
 
This approach exploits the different vapor pressures of oxides of molybdenum and technetium. 
MoO3 melts at about 800 C and at this temperature the vapor pressure of Tc2O7 is about five 
orders of magnitude greater than that of MoO3. If a flow of oxygen is maintained over the 
molten  MoO3, the Tc2O7 will be transported downstream and will condense when the 
temperature falls below 400 C. Idaho National Laboratories[9] refined the procedure and 
showed that good separation efficiency could be obtained. This is the technique that Best 
Cyclotron Systems is planning to use[12] to separate 99mTc from 100Mo targets irradiated by 
proton beams.  
Chromatographic Column (ABEC) 
 
This technique is based on the use of two aqueous systems which are immiscible. If the 
technetium oxide is soluble in one of the phases but not the other, then these aqueous biphasic 
systems (ABS) can provide a route for separating technetium from molybdenum. Rogers et al[13] 
developed a technique for attaching the active component, polyethylene glycol, of one of the 
phases to a solid support so that, when the second liquid phase is present, ABS-like conditions 
are established. The column, loaded with the active component, is referred to as an aqueous 
biphasic extraction column, or ABEC. The technetium oxide is retained on the column and will 
be washed off when the mobile phase is changed to water. This approach has been developed 
and refined by NorthStar Medical Radioisotopes[14] and an animal study has shown that the 
product of the NorthStar ARSII separator meets or exceeds the specifications of that from a 
technetium generator[15].  
ACTIVE PROPOSALS 
 
There have been many proposals in the past few years for addressing the short-fall in the 
supply of 99Mo/ 99mTc. Some proponents advocate the construction of new reactors for the sole 
purpose of producing radioisotopes. Others require sophisticated accelerator technology for 
driving sub-critical assemblies. We restrict our considerations to those projects that have 
advanced well beyond the planning stage and have some likelihood of contributing to the 
supply of 99Mo/ 99mTc within the next few years. 
Reactors 
 
The OPAL research reactor in Australia began operation in 2007. It is fueled with LEU and uses 
LEU targets for isotope production. It presently produces less than 5 % of the global 
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requirements for 99Mo but a decision was taken in 2012 to greatly expand the production of 
medical isotopes and a new processing facility is now under construction[16]. It is scheduled to 
begin production in 2016 and be capable of producing up to 30 % of the world’s requirements. 
They have also committed to a new facility for processing the radioactive waste and it is 
scheduled to begin operation in 2017. This is the only significant new source of fission 99Mo 
that will be available before NRU is shut down in March 2018. 
Neutron Capture 
 
The irradiation of 98Mo in a nuclear reactor has been used in the past to produce small 
quantities of 99Mo. NorthStar Medical Radioisotopes[5] is planning to make significant quantities 
of 99Mo for the US market by irradiating molybdenum targets in the Missouri Research Reactor 
(MURR). The irradiated targets will be processed by NorthStar to form molybdate, which will be 
shipped to participating nuclear pharmacies. Each of these will be equipped with the NorthStar 
RadioGenix separator which is based on ABEC column technology. Their proposal is well 
advanced and has been submitted to the FDA for regulatory approval. They project being able 
to produce modest amounts of 99Mo during 2015 and 50 % of US requirements by the end of 
2016. This project faces the challenge of being based on a single aging reactor without any 
backup but the production technology is well established. 
Sub-Critical Assemblies 
 
This approach aims to retain the advantage of producing 99Mo with high specific activity while 
avoiding some of the challenges of operating a nuclear reactor. SHINE Medical Technologies[17] 
propose using neutron generators based on the D-T fusion reaction to inject neutrons into a 
aqueous solution of low-enriched uranium. Referred to as a Subcritical Hybrid Intense Neutron 
Emitter, or SHINE, the neutrons from the generator will be multiplied by a beryllium reflector 
and by fission neutrons but the solution will remain subcritical. Because the fission products are 
produced in an aqueous solution separation of the molybdenum isotopes will be simplified. 
Although aiming to produce about half of US requirements for 99Mo, the start-up date for 
SHINE has been pushed back and is now planned for 2018. The neutron generator technology is 
the most demanding aspect of the project. By using a gaseous tritium target, the proponents 
aim to greatly lengthen the lifetime of traditional D-T neutron generators. However, it means 
they need a large tritium inventory and techniques for purifying the tritium gas as it is quickly 
diluted by the deuteron beam. In short, the proposed neutron generator technology has not yet 
been proven in an industrial setting. 
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Cyclotrons 
 
Two Canadian consortia[18] as well as Best Cyclotron Systems[12] are working on the direct 
production of 99mTc using cyclotrons and the reaction 100Mo(p,2n)99mTc. The TRIUMF group[19] 
recently announced the successful production of clinically useful quantities of 99mTc. Because 
the half-life of 99mTc is only six hours, in order for this approach to service a large distributed 
population, major changes in the entire model of production and distribution will be required.  
It will be much closer to the model of production of PET isotopes, requiring a local cyclotron 
and local target handling, including the recovery of used target material. To meet all of 
Canada’s requirements for 99mTc may require some cyclotrons dedicated to its production. It 
may be a challenge to mount this scale of effort by 2018, let alone any time during 2016.  
However, cyclotrons should provide some Canadian cities with a reliable source of 99mTc as 
early as 2016 and will provide a good demonstration of the overall process.  
Electron Linear Accelerators 
 
Although several groups have used the (, n) reaction to produce small amounts of 99Mo in the 
past, Idaho National Laboratories[9] were the first to study the possibility of producing large 
quantities of 99Mo. Their work, which was carried out in the late 1990s, was not commercialized 
because it was assumed the MAPLE reactors would produce a robust supply of medical 
isotopes.  
Both NorthStar in the US and the new facility at the Canadian Light Source Incorporated (CLS) in 
Canada plan to use electron linacs to produce 99Mo via the (γ,n) reaction.  The CLS is 
collaborating with the Winnipeg Health Sciences Centre to qualify the 99Mo and to develop a 
separation unit for use in Canada. The objective is to meet most of the requirements of 
Manitoba and Saskatchewan by the end of 2016. An additional linac in a new facility will be 
required to meet a larger fraction of Canada’s needs and this may be in place by 2018. 
NorthStar plans to install 16 linacs at one facility in Beloit, Wisconsin[5] that is reported to be 
capable of producing 50 % of the US requirements. 
Industrial electron accelerator technology is well developed and extensively used for radiation 
processing. The additional challenges that arise when irradiating molybdenum targets are 
related to the beam window that must handle the pulsed, high-current beam and the removal 
of heat from the molybdenum target. Conventional water cooling is capable of removing the 
heat but may lead to complications due to water radiolysis. NorthStar is working with US 
national laboratories to establish target cooling using helium gas[20].  
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ISOTOPICALLY ENRICHED MOLYBDENUM 
 
The neutron capture process requires 98Mo for which the natural abundance is about 24 %.  The 
NorthStar/MURR proposal to produce up to 50 % of US demand by this process will require 
many kilograms of enriched 98Mo and routine reprocessing of target material. Natural 
molybdenum has been used in the past but 95Mo, with an abundance of 16 %,  has a high 
neutron cross section that will reduce the neutron flux and there is not sufficient irradiation 
space (with high neutron flux) to irradiate the required volume of natural molybdenum to meet 
the production requirements. Because the irradiation of 98Mo in MURR is viewed as a short-
term solution until the NorthStar electron accelerators begin operation, the long-term 
availability of enriched 98Mo is not a critical issue. 
The (, n) and (p, 2n) reactions require 100Mo for which the natural abundance is less than 10 %. 
Thus, the availability of molybdenum enriched with 100Mo is critical because it gives a ten-fold 
increase in yield over what could be achieved with naturally occurring molybdenum. If all of 
Canada’s requirements for 99Mo were to be met using linacs, an inventory of less than 2 kg of 
100Mo would be required[6]. Presently, 100Mo can be produced using centrifuges in Zelenogorsk, 
Russia at a rate of about 30 kg per year[21].  Isotopic purity is not important for the (, n) 
reaction but is more critical for the (p, 2n) reaction because other isotopes of molybdenum will 
lead to unwanted radioisotopes that will increase the patient dose. 
Because only a small fraction of 98Mo or 100Mo is converted to 99Mo during each irradiation and 
because the isotopically enriched material is expensive it will be necessary to recover and 
recycle the target material. Tests have shown that this can accomplished with modest effort 
and with losses less than 5 %. Thus, once an initial inventory is established, it will only be 
necessary to replace the material lost during each cycle. For Canada, this would be less than 
1 kg of 100Mo per year. 
There is presently only one supplier of isotopically enriched molybdenum so in the long term a 
more robust supply chain will need to be developed. Urenco (Netherlands) operates centrifuges 
for uranium enrichment and has produced small quantities of molybdenum in the past. 
Advanced Applied Physics Solutions[22] has shown that it is practical to magnetically separate 
relevant quantities of 98Mo and 100Mo.  Although not as far advanced, a new approach based on 
laser isotope separation[23] has been suggested as a way to produce 100Mo. Once a clear market 
is established new suppliers of isotopically enriched molybdenum will likely emerge. It is also 
worth noting that this material can be stockpiled indefinitely. 
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ECONOMICS 
 
The purchase price of 99mTc in 2015 is about $2/mCi or about $40 for a typical scan and 
represents only about 15 % of the total cost of a SPECT procedure. Concern has been raised 
that much of the present cost of producing 99Mo in research reactors is subsidized, especially 
regarding the cost of waste management.  The OECD has carried out an economic study[24] and 
show that, presently, the reactor cost represents less than 0.4 % of the final cost of a unit of 
99mTc. Under their worst-case full cost recovery model, this percentage needs to increase to 
about 3 %.  Although this represents a very significant increase to the cost charged by the 
reactor operators it has only a small effect on the cost of 99mTc to the end user.  
Few of the new proposals have provided cost estimates but a report prepared for the American 
Association for the Advancement of Science[25] has attempted to use available data to estimate 
the cost of producing a dose of 99mTc. They indicate that the production cost using electron 
accelerators will be about 35 % of that using reactors, while the cyclotron cost will be similar or 
slightly less than the reactor cost, depending on whether or not it is a dedicated or 
multipurpose cyclotron. We are not aware of cost estimates for the NorthStar/MURR or SHINE 
proposals. 
Although there have been several reports suggesting that new production methods will lead to 
very substantial price increases for 99mTc to the end user the available data does not indicate 
that this will be the case. 
PREDICTIONS 
 
Having reviewed the main scientific, engineering and economic issues regarding the production 
of 99Mo or 99mTc, we will now attempt some predictions regarding the future supply. 
99mTc is, by a large margin, the most widely used radioisotope for nuclear medicine procedures 
and there is strong support for its continued availability. Thus, a market for 99mTc seems assured 
for the indefinite future. 
Five research reactors have reliably produced most of the world’s requirements of 99Mo for 
many years except during the NRU crisis of 2007 and when both NRU and HFR (Netherlands) 
were down for unscheduled repairs during 2010. Once NRU stops routine production of 99Mo, 
North America will not have a local reactor supplying the demand for 99mTc for the first time in 
many years. Europe will still be in a state of flux as aging reactors are shut down (Osiris in 
France during 2015) or refurbished (BR2 in Belgium) and replacements are delayed. The only 
new reactor project that will likely be ready to produce a significant quantity of 99Mo in the next 
Page 12 of 21 
 
few years is the OPAL reactor in Australia. Their maximum production rate is estimated to be 
about 30 % of global requirements so not enough to replace NRU and Osiris production.  
The SHINE project has been delayed because of financial and technical challenges and they are 
still awaiting regulatory approval to begin construction. It is not likely to contribute any 99Mo 
before NRU shuts down. 
Within Canada, direct production of 99mTc via cyclotrons may be approved and ready for use in 
the areas near the major players in this field (Vancouver, Edmonton, Sherbrooke and Montreal 
with modest quantities in London and Hamilton) by the end of 2016 although it would not be 
surprising if regulatory approval delays start-up. 
The Canadian linac project will likely produce some supply in Canada (Manitoba and 
Saskatchewan) by the end of 2016 but it is unlikely that regulatory approval will be obtained in 
that time frame. It will require an additional linac in a new facility to increase that supply to 
cover most of Canada. Depending on financing, that may be available during 2018. 
The NorthStar/MURR project, using the neutron capture reaction with 98Mo, is the new 
initiative most likely to be producing significant commercial quantities of 99Mo in the next few 
years. They have already produced more than 400 Ci of 99Mo in a test run and their separator is 
undergoing review to obtain the necessary approvals. Their goal is to be producing about half of 
the US requirements by the end of 2016. 
It is likely that large areas of Canada and the US will still require fission 99Mo between now and 
2018 and that will need to come from OPAL and will likely require support from NRU. The 
demands for NRU production could also come from reduced European production during that 
time with the closure of Osiris.  
Looking beyond 2018, there will likely continue to be significant supplies of reactor-produced 
material for several years, perhaps approaching 50 % of demand. Although there is pressure to 
establish prices that reflect full cost recovery, there are indications that this will not greatly 
increase the cost to the end user[24]. One of the great strengths of 99Mo produced by the fission 
of 235U is the simplicity of the generator used to “milk” the 99Mo column and as long as these 
units are available they will likely find a market. However, it is generally recognized that 
significant scheduling conflicts arise when research reactors are also used to produce a 
commercial product. The significant waste stream from the fission targets, which will increase 
in size as reactors convert to the use of LEU targets, is another reason why reactor production 
may decrease as other methods come on line. 
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Reactor irradiation of 98Mo avoids the problem of waste from fission targets. However, the 
NorthStar/MURR approach is based on an aging reactor fueled with HEU and which has no 
backup. As recognized by NorthStar, this can be at best a short-term solution and it is being 
used until their linac facility is established. 
Although it has been demonstrated that suitable cyclotrons exist to produce relevant quantities 
of 99mTc, several facilities must be established in or near major population centres. Each of 
these will require staffing with highly qualified personnel and must establish manufacturing 
practices and quality systems related to the production of 99mTc. If robust supplies of 99Mo are 
available, it seems unlikely that nuclear pharmacies will want to devote the effort to obtaining 
cyclotron-produced 99mTc. This means that cyclotron beam time will not be taken away from 
producing the very short-lived isotopes that are important to PET imaging and cannot be 
produced any other way. Nevertheless, cyclotrons may be an important source of 99mTc in the 
short term if other sources of 99Mo are significantly delayed. 
We believe that using electron accelerators to irradiate 100Mo targets will turn out to be the 
best long term solution for producing 99Mo. Industrial linacs, such as that pictured in Figure 3, 
are widely used for radiation processing so the technology is mature. Although these machines 
are generally restricted to energies below 10 MeV to avoid activation, Mevex Corporation has 
shown that it is straightforward to add additional sections to achieve the optimum energy for 
99Mo production. A single national or regional facility can host several linacs with the size of the 
facility easily scalable, depending on demand. No uranium of any kind is required and there is 
negligible radioactive waste. Regulatory licensing is much simpler than for a reactor and the 
cost is much less. The facility is committed to making a commercial product so there are no 
competing demands for beam time. The cost per unit dose of 99mTc is estimated to be less than 
that produced by a reactor. 
The main change from the point of view of the nuclear pharmacy is that that they will use 
different technology for separating the 99mTc from the parent solution of 99Mo. As discussed 
earlier, several separation technologies exist and have been tested in laboratory settings but 
the approach based on the ABEC column and developed by NorthStar (Figure 4) is the closest to 
field deployment. Each nuclear pharmacy would have one (or more) of these units and would 
receive shipments of solution containing 99Mo from the NorthStar linac farm in Beloit, 
Wisconsin. When the solution has decayed beyond use, it would be returned to NorthStar for 
recycling. 
The next two to three years will likely see some uncertainty in supply as different technologies 
are used to produce varying amounts of 99Mo or 99mTc. Beyond that, it can be expected that 
NorthStar will be producing large quantities of 99Mo. If SHINE and some of the proposed reactor 
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projects come on-line, it might be that there will be a significant excess manufacturing 
capability by 2020. 
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Figure 1. Performance of a typical technetium generator when milked every 24 hours. The decay of 
99
Mo with a 
half-life of 66 hours is shown by the upper curve. The generator was initially loaded with 10 Ci and has been 
milked at zero hours to remove the 
99m
Tc that has formed on the alumina column. 
99
Mo decays to 
99m
Tc over the 
next 24 hours at which time the column is milked again. This process can be repeated for about two weeks. 
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Figure 2. Typical components of a technetium generator. The molybdenum oxide is loaded on the alumina 
column by the manufacturer. The molybdenum decays to technetium and the resulting technetium oxide can be 
washed off the column using a salt solution. The process can be repeated for up to two weeks, by which time 
the molybdenum activity will be about 3 % of its original value. (Figure courtesy of the IAEA Human Health 
Campus). 
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Figure 3. Drawing of the 35 MeV, 40 kW linac manufactured by Mevex Corporation (Stittsville, Ontario) and 
installed at CLS. The molybdenum target station is to the right, at the end of the machine and the complete 
assembly is about 6.5 m long. The molybdenum target is comprised of a series of discs, each about 1 cm in 
diameter. The shielding around the target assembly serves to localize induced activity, thus permitting assess to 
the room shortly after the end of irradiation. The three modulators to supply the RF power to the waveguides 
are installed in a separate area (Drawing courtesy of the Canadian Light Source). 
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Figure 4. RadoGenix separator developed by NorthStar for separating 
99m
Tc from a solution of 
99
Mo. The unit is 
fully automated, operates at room temperature, does not require a fume hood and has a separation efficiency 
greater than 90 %. The required reagents are held in the clamshell structure at the top; the ABEC separation 
column is in middle unit on the top shelf and the 
99m
Tc product is delivered to the module on the right; up to 
four 
99
Mo sources can be loaded on the middle shelf; reagent waste is stored on the bottom shelf. The unit is 
presently undergoing assessment for US FDA approval. (Photo courtesy of NorthStar Medical Radioisotopes). 
